openPR Logo
Press release

Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX) Investor Notice: Investigation over potential Wrongdoing

01-29-2022 04:58 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of investors in Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares over potential wrongdoing.

An investigation on behalf of investors in Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares over potential wrongdoing.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc.

Investors who purchased shares of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Salt Lake City, UT based Kiora Pharmaceuticals, Inc., formerly EyeGate Pharmaceuticals, Inc.,, an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States.

Kiora Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $2.68 million in 2019 to $0.012 million in 2020, and that its Net Loss increased from $7.09 million in 2019 to $8.17 million in 2020.

Shares of Kiora Pharmaceuticals, Inc f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX, formerly NASDAQ: EYEG) declined from over $12 per share in late 2019 to as low as $0.63 per share on January 24, 2022

On January 28, 2022, NASDAQ: KPRX shares closed at $0.72 per share.

Those who purchased shares of Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX, formerly NASDAQ: EYEG) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Kiora Pharmaceuticals, Inc. f.k.a. EyeGate Pharmaceuticals, Inc. (NASDAQ: KPRX) Investor Notice: Investigation over potential Wrongdoing here

News-ID: 2540314 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Pharmaceuticals

Cystic fibrosis Market: Epidemiology, Therapies, Companies, DelveInsight | Veron …
Cystic fibrosis therapies, such as TRIKAFTA, SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, and others, are expected to boost the Cystic fibrosis Market in the upcoming years. DelveInsight has launched a new report on "Cystic fibrosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cystic fibrosis, historical and forecasted epidemiology as well as the Cystic fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France,
Gastritis Drugs Market Size Report 2032 | Regeneron Pharmaceuticals, Sanofi, Han …
DelveInsight's "Gastritis Market Insights, Epidemiology, and Market Forecast -2032" report delivers an in-depth understanding of the Gastritis, historical and forecasted epidemiology as well as the Gastritis market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Key Takeaways from the Gastritis Market Research Report • The increase in Gastritis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging
Generic Pharmaceuticals Market Set for More Growth| Hikma Pharmaceuticals, Emcur …
Advance Market Analytics published a new research publication on "Generic Pharmaceuticals Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Generic Pharmaceuticals market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample Copy of
Global Halal Pharmaceuticals Market 2019 - CCM Pharmaceuticals, Pharmaniaga, Ros …
This new report by Eon Market Research, titled “Global Halal Pharmaceuticals Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Halal Pharmaceuticals industry at a global as well as regional and country level. Key facts analyzed in this report include the Halal Pharmaceuticals market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study
Topical Antibiotic Pharmaceuticals Market 2016-2026 | Teva Pharmaceuticals, Perr …
Topical antibiotics are applied to a certain area of the skin to kill infections. Application of topical antibiotics has a number of advantages upon comparison of systemic delivery in the treatment of skin infections. Skin and soft tissue infections (SSTIs) involve microbial invasion of the skin and underlying soft tissues infections are one of the most commonly occurring conditions amongst people. Most of these infections are minor and chronic in
Lipid Disorder Treatment Market to 2017 - 2026: Teva Pharmaceuticals, Mylan Phar …
Researchmoz added Most up-to-date research on "Lipid Disorder Treatment Market - Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2026" to its huge collection of research reports Extensive research report on global lipid disorders treatment market skilfully crafted by Transparency Market Research depicts the current as well as future scenario of various drugs used to treat lipid disorders. The research study includes analysis on key developments that are